Introduction: The kidneys' ability to filter drug substances deteriorates with age. Some diseases accelerate this degradation. Patients with renal impairment are at increased risk of drug-related adverse reactions if dose adjustments are not made. Aim: To investigate the purchase and dosage of newly introduced opioids, gabapentinoids and NSAIDs between 2014 and 2019 for patients with impaired kidney function in the Stockholm Region. Method: A register-based cross-sectional study where data has been obtained from the database SCREAM (The Stockholm CREAtinine Measurements project). All patients ≥ 18 years of age, who live in Stockholm and have performed at least one creatinine measurement from January 2013 and received a prescription for selected drugs were included. The number of people and the dosage (DDD/prescription) were studied annually, by age, sex, and CKD. Results: The total number of patients was 362,964 with a mean age of 56 (SD 19) years. The study included 202,762 women (56%) and 160,201 men (44%). The mean value of eGFR was 88 (SD 24). Gabapentinoids were prescribed significantly less than NSAIDs and opioids, however, prescribing increased between 2014-2018. It was the only class of drugs with a clear reduction in dosage with respect to CKD level. NSAIDs were prescribed on few occasions to patients with impaired renal function, at the same time a reduction in the total number of prescriptions was seen between 2014-2018. No major difference in dosage was seen based on the patient's CKD level. Opioids were prescribed on most occasions with an increase in the number of prescriptions between 2014-2018. Only minor differences in dosage were noted between the different CKD levels. However, for all CKD levels, there had been a gradually reduced dosage from 2014 to 2018. Conclusion: Patients with renal impairment belong to a fragile group with a number of different comorbidities. Painkillers are prescribed on fewer occasions to patients with renal impairment. Prescribers, however, do not appear to adjust the dose with respect to renal function when re-introducing NSAIDs and opioids